Ovarian Cancer: Making the “Silent” Disease Visible and Managing Recurrence

Ovarian cancer is often called a “silent killer” because early symptoms can be vague and no effective routine screening test exists for the general population. Many patients are diagnosed only after the disease has spread within the abdomen. Yet “silent” should not mean hopeless. Expert surgery, platinum-based chemotherapy, maintenance treatment, genetic testing, and structured recurrence management have created longer periods of disease control for many patients.

The most important early decisions are whether the patient should undergo primary surgery or receive chemotherapy first, whether complete removal of visible disease is realistically achievable, and whether the tumor carries biomarkers that can guide maintenance treatment and future therapy.

Why Ovarian Cancer Is Often Found at an Advanced Stage

The ovaries lie deep in the pelvis, and a growing tumor may not cause a clear symptom at first. High-grade serous ovarian cancer can spread across the lining of the abdomen before a large ovarian mass is obvious.

Symptoms may include persistent bloating, increasing abdominal size, pelvic or abdominal pain, feeling full quickly, reduced appetite, urinary urgency or frequency, constipation, fatigue, back discomfort, unexplained weight change, or shortness of breath from fluid around the lungs.

These symptoms are common and usually have non-cancer causes. What matters is a new pattern that is persistent, frequent, progressive, or different from normal. Severe pain, vomiting, inability to eat, breathing difficulty, or rapid abdominal swelling requires prompt medical attention.

For an overview of diagnosis and treatment pathways, read our ovarian cancer treatment guide for international patients in Shanghai.

Why There Is No Simple Screening Test

Transvaginal ultrasound and the CA-125 blood test are useful in evaluating a suspicious mass and monitoring selected diagnosed patients. However, they have not proved accurate enough to serve as routine screening for all average-risk women. CA-125 can be normal in some cancers and elevated because of benign conditions such as endometriosis, menstruation, fibroids, infection, or liver disease.

For average-risk people without symptoms, routine ultrasound and tumor-marker testing may create false alarms, unnecessary surgery, or false reassurance. High-risk patients with inherited susceptibility require individualized counseling and risk-management plans rather than casual annual testing.

Diagnosis: Confirm the Type, Stage, and Surgical Strategy

“Ovarian cancer” includes several diseases. High-grade serous carcinoma is the most common, but endometrioid, clear cell, low-grade serous, mucinous, germ-cell, and sex-cord stromal tumors have different biology and treatment.

Evaluation may include pelvic examination, transvaginal ultrasound, contrast-enhanced CT of the chest, abdomen, and pelvis, MRI in selected cases, laboratory tests, and pathology. Image-guided biopsy may be used when chemotherapy is planned before surgery or when the diagnosis is uncertain.

A gynecologic oncologist should review the distribution of disease, the patient’s general condition, nutrition, organ function, and likelihood of complete cytoreduction before deciding the treatment sequence.

R0 Cytoreduction: Why Complete Removal Matters

For advanced epithelial ovarian cancer, the amount of visible disease remaining after surgery is one of the strongest factors associated with outcome. R0 cytoreduction means that no visible tumor remains at the end of the operation.

Achieving R0 may require more than removal of the ovaries and uterus. Depending on disease distribution, surgery can involve the omentum, peritoneum, bowel, diaphragm, spleen, lymph nodes, or other affected structures. This makes ovarian cancer surgery a multidisciplinary abdominal operation rather than routine gynecologic surgery.

The objective is not the most aggressive operation at any cost. The team must balance the likelihood of complete removal against surgical risk, recovery time, organ function, and the need to begin chemotherapy without excessive delay.

Primary Surgery or Chemotherapy First?

Some patients are best treated with primary cytoreductive surgery followed by chemotherapy. Others may receive neoadjuvant chemotherapy first, followed by interval surgery if imaging, biomarkers, and clinical condition indicate that complete removal has become more achievable.

Factors supporting chemotherapy first can include extensive disease that is unlikely to be completely removed initially, poor physical condition, severe nutritional decline, significant medical comorbidity, fluid around the lungs, or the need to stabilize organ function.

Diagnostic laparoscopy can sometimes help the team assess whether R0 surgery is feasible without committing the patient to a major open operation. The sequence should be selected by an experienced gynecologic oncology team rather than by stage alone.

First-Line Chemotherapy

Platinum-based chemotherapy, commonly combined with a taxane, remains a foundation of first-line treatment for epithelial ovarian cancer. Treatment may be given after primary surgery or around interval surgery. Bevacizumab or other agents may be considered for selected patients according to stage, risk, medical condition, local approval, and treatment plan.

Side effects can include low blood counts, infection risk, fatigue, nausea, hair loss, neuropathy, allergic reactions, kidney effects, and other complications. Dose and schedule adjustments can help maintain treatment safely and should not automatically be viewed as failure.

PARP Inhibitor Maintenance: Extending Disease Control

PARP inhibitors have changed maintenance treatment after a response to platinum-based chemotherapy. They can delay progression for selected patients, particularly when the tumor has a BRCA mutation or homologous recombination deficiency, often called HRD.

The expected benefit and medicine choice depend on BRCA status, HRD results, response to platinum, previous treatment, regulatory availability, and individual risk. PARP inhibitors are not standard for every ovarian tumor or every clinical situation.

Monitoring is essential because these medicines can cause anemia, low platelets or white blood cells, fatigue, nausea, and other adverse effects. Rare but serious bone-marrow complications can occur. Patients should follow the prescribed blood-test schedule and report unusual bruising, infection, shortness of breath, or persistent fatigue.

BRCA Testing and Family Risk

Patients with epithelial ovarian cancer should discuss genetic counseling and germline testing, regardless of age or family history, because an inherited BRCA1, BRCA2, or other relevant variant may affect treatment and relatives. Tumor testing may also identify acquired changes that are not inherited.

A positive germline result can guide PARP inhibitor decisions and help relatives understand their own risk of ovarian, breast, pancreatic, prostate, or other cancers. A negative BRCA result does not mean the tumor lacks all DNA-repair abnormalities, and an uncertain variant should not be treated as a confirmed harmful mutation.

Relatives should receive their own genetic counseling rather than ordering broad tests without interpretation. Risk-reducing surgery may be discussed for confirmed high-risk carriers after childbearing, but timing and the resulting early menopause require careful planning.

Shanghai Expertise: Advanced and Recurrent Ovarian Cancer

The gynecologic oncology team led by Prof. Zang Rongyu at Zhongshan Hospital, Fudan University has focused on advanced and recurrent ovarian cancer, complex cytoreductive surgery, clinical research, and translational work aimed at understanding treatment response and recurrence.

The value of a specialist center lies in coordinated review by gynecologic oncology, medical oncology, pathology, radiology, genetics, surgery, nutrition, rehabilitation, and supportive care. Difficult decisions, including whether recurrent disease should be operated on again, require careful selection rather than a universal rule.

For a broader view of available services, visit our gynecologic oncology treatment guide for Shanghai.

Recurrence: A New Decision, Not Simply a Repeat of First-Line Care

Ovarian cancer can recur even after a strong initial response. Treatment depends on the time since platinum therapy, previous maintenance treatment, BRCA and HRD status, location and volume of recurrence, symptoms, general condition, organ function, and patient priorities.

Options may include platinum-based or non-platinum chemotherapy, targeted or maintenance therapy, secondary cytoreductive surgery for carefully selected patients, radiotherapy for local control or symptom relief, and clinical trials.

The older terms “platinum-sensitive” and “platinum-resistant” remain useful but do not capture every clinical detail. The care team should review the full treatment history and tumor behavior before choosing the next line.

Secondary Surgery for Recurrent Disease

Some patients with a limited first recurrence, good performance status, favorable treatment-free interval, and a realistic chance of complete removal may benefit from secondary cytoreductive surgery. The key is selection. Surgery that leaves substantial residual disease may add risk without providing the intended benefit.

High-quality imaging, surgical expertise, and multidisciplinary review are essential. Patients should ask whether the center expects R0 resection and what evidence supports surgery in their specific pattern of recurrence.

Emerging Treatments and Clinical Trials

Research is exploring new antibody-drug conjugates, anti-angiogenic strategies, immunotherapy combinations, DNA-damage response targets, folate receptor-directed therapies, and treatments tailored to less common ovarian cancer subtypes.

Immunotherapy alone has limited activity in many unselected ovarian cancers, so trial eligibility and biomarker context matter. Patients should ask the trial phase, treatment goal, known risks, additional tests required, and which standard treatments remain available afterward.

Quality of Life During Long-Term Treatment

Managing ovarian cancer often means managing repeated treatment and recovery. Support may include:

• Nutrition care for early fullness, bowel symptoms, weight loss, or fluid accumulation;
• Prevention and treatment of blood clots;
• Management of neuropathy, fatigue, nausea, anemia, and sleep problems;
• Pelvic-floor, abdominal, and general physical rehabilitation;
• Menopause, sexual health, fertility, and body-image support;
• Early palliative care for symptoms alongside anticancer treatment;
• Psychological support for recurrence anxiety and family stress.

Supportive care is part of active cancer treatment. It helps patients remain strong enough to receive therapy and protects daily function.

Questions for the Gynecologic Oncology Team

• What is the exact pathology and stage?
• Is primary surgery or neoadjuvant chemotherapy more appropriate?
• Does the team expect an R0 resection?
• Would diagnostic laparoscopy improve treatment planning?
• Are germline BRCA testing, tumor BRCA testing, and HRD testing indicated?
• Is maintenance treatment recommended after chemotherapy?
• How will blood counts and other PARP inhibitor side effects be monitored?
• If the disease recurs, could secondary surgery or a clinical trial be appropriate?
• How will nutrition, bowel symptoms, menopause, and emotional health be supported?

International patients planning care can also review how to access gynecology and gynecologic oncology in Shanghai. A related advanced ovarian cancer case illustrates the role of specialist multidisciplinary care.

How CMCS Supports International Patients in Shanghai

China Medical Concierge Shanghai (CMCS) is a health management and medical concierge company, not a hospital. We help international patients organize medical information, identify appropriate specialists in Shanghai, and coordinate care before, during, and after appointments.

Depending on the case, CMCS can assist with:

• Organizing pathology, operative notes, CT or MRI, CA-125 trends, BRCA or HRD results, and previous treatment records;
• Coordinating evaluation by gynecologic oncology, medical oncology, genetics, surgery, nutrition, rehabilitation, or a multidisciplinary team;
• Preparing a concise bilingual case summary and prioritized consultation questions;
• Supporting appointment planning, travel preparation, on-site communication, and examination scheduling;
• Helping patients track surgery, chemotherapy, maintenance treatment, side effects, and surveillance milestones;
• Facilitating necessary communication with family members after receiving the patient’s authorization.

Remote record review or video consultation requires the physician’s approval and may not replace an in-person examination. Patients should provide authorization and complete, recent medical records before case coordination. CMCS can usually address approximately three to five core questions during initial screening. If specific medical coordination is required, the service scope and applicable fee will be explained in advance.

Conclusion: Make the “Silent” Disease Visible

There is no reliable routine screening test for average-risk women, so ovarian cancer awareness depends on recognizing persistent symptoms, identifying inherited risk, and referring suspicious findings to gynecologic oncology without delay.

After diagnosis, the pathway should be visible and deliberate: determine whether R0 surgery is achievable, use platinum chemotherapy effectively, test BRCA and HRD where appropriate, select maintenance treatment carefully, and reassess each recurrence as a new multidisciplinary decision.

Contact CMCS

For help organizing ovarian cancer records, connecting with appropriate specialists in Shanghai, or planning a medical visit, contact us:

• Website: www.medicalsh.com
• Email: contract@medicalsh.com
• WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1

You may also submit your information through our contact page.

Medical notice: This article is for health education only and does not provide a diagnosis or individualized treatment advice. Imaging, pathology, surgery, chemotherapy, maintenance treatment, genetic testing, and follow-up plans must be determined by qualified physicians using the patient’s complete medical information.